Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
AddLife is continuing its expansion in Europe by acquiring BioCat GmbH ("BioCat"), for inclusion in its Labtech business area. BioCat is a specialized distributor of products and services to the life science research market with annual revenues of EUR 9m. The company is located in Germany but also has sales in Austria and Switzerland, giving AddLife the opportunity for further expansion in these markets.
BioCat offers a wide portfolio of instruments and research reagents within the fast-growing fields of genomics, proteomics and cell biology to academia as well as to the pharma and biotech industry. The company distributes products and services from approximately 70 suppliers.
The acquisition strengthens AddLife's presence in Germany and opens up opportunities for cooperation with our other companies in Europe that are active in the same product segment.
BioCat has a turnover of approximately EUR 9m and is located in Heidelberg, Germany. The business has its own sales force but also sales through a web shop. The majority of the 20 employees work within sales and support.
"The acquisition of BioCat is a first step for Business area Labtech into the German market in an interesting segment where we already have major expertise and market presence in several other European countries", says Kristina Willgård, CEO of AddLife AB
"BioCat is very proud and happy to become a member of the AddLife family. We have been very impressed by AddLife's attitude, competencies and strategic vision right from the beginning. Together we will further develop BioCat as most distinguished distributor for Life Science Research products and services in the DACH region and will continue our very successful journey" says Dr. Michael Hartmann, CEO of BioCat GmbH.
The acquisition is completed as of today and expected to have only a marginal positive effect on AddLife's earning per share in the 2022 financial year.
Stockholm, 1 April 2022
AddLife AB (publ)
For further information, please contact
Kristina Willgård, CEO, AddLife AB, +46 (0)705 10 12 23
Peter Simonsbacka, Labtech Business Area Manager, AddLife AB, +46 (0)702 87 00 87
AddLife is an independent European player in Life Science that offers high-quality products, services and consulting to both the private and public sectors. AddLife has about 2,200 employees in around 80 operating subsidiaries, which operate under their own brands. The Group has annual sales of approximately SEK 8 billion. AddLife is listed on the NASDAQ Stockholm stock exchange.
This information was submitted for publication on 1 April 2022 at 13:30 CET.